Oct. 13 at 3:12 PM
H.C. Wainwright reiterated
$ABEO Buy/
$20
$KRYS
HCW said:
Last week, Abeona Therapeutics announced the activation of Children's Hospital Colorado as the newest qualified treatment center (QTC) for Abeona's marketed product ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Children's Colorado in Aurora, CO—one of the pioneering institutions that provide advanced levels of care for people with epidermolysis bullosa (EB) and a member of the EB Clinical Research Consortium—has completed the applicable QTC start-up activities, enabling the initiation of patient identification for scheduling of ZEVASKYN treatment.
In our view, the establishment of another QTC demonstrates Abeona's continued execution with respect to the rollout of ZEVASKYN.
We reiterate our Buy rating and 12-month price target of
$20.
